The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)

interests; (IP) Intellectual property rights/inventor/patent holder Background. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a significant health burden. We aimed to evaluate and compare the ef-ficacy and tolerability of single-agent sorafenib in treating elderly patients with advanced HCC versus the younger population. Methods. We retrospectively analyzed a consecutive co-hort of advanced HCC patients with Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group performance status score of 0 –2 treated with sorafenib. The patients were categorized into older (age>70 years) and younger (age <70 years) groups. Treat-ment outcomes and related adverse events (AEs) were compared